(A) Percentage of time spent on the open arm of the elevated plus maze (EPM) in non-selected Wistar (W) and msP rats pretreated with doses of the fatty acid amide hydrolase (FAAH) inhibitor PF-3845 (3 or 10 mg/kg, i.p., n=12–15 per dose and genotype) or vehicle (VEH, n=19–20 per genotype). (B) Total entries made into the closed arm of the EPM in rats from A. (C) Latency to drink from a palatable chocolate solution during novelty stress in Wistars and msPs pretreated with PF-3845 (10 mg/kg, i.p., n=8–9 per genotype) or VEH (n=9–11 per genotype). (D) Total volume of chocolate solution consumed in rats from C. Data expressed as mean ± SEM. Asterisks (*) denote significant genotype differences, whereas plus signs (+) denote significant differences relative to vehicle controls (p<0.05). A continuous line across groups denotes significant main effects.